Sentinel lymph node biopsy for localised ductal carcinoma in situ?

Research output: Contribution to journalArticlepeer-review


Intraductal carcinoma of the breast (DCIS), by definition, cannot give axillary metastases. Axillary dissection is therefore not indicated. The role of the sentinel lymph node (SLN) biopsy in the management of DCIS has not yet been established. A 6-13% risk of SLN involvement is reported in Literature. The aim of the present study is to assess the role of SLN biopsy in patients with pure DCIS and attempt to identify guidelines for routine practice in managing such patients. From March 1996 to December 2003, 508 consecutive patients with pure DCIS of the breast underwent SLN biopsy at the European Institute of Oncology in Milan. Clinical and pathological data were prospectively collected. In all cases of previous surgery or stereotactic biopsy performed elsewhere all pathological slides were reviewed. Cases with microinvasion were excluded from this investigation. Lymphatic mapping was performed using a radiocolloid technique. Most of the patients underwent conservative surgery and removal of the SLN which was sent for conclusive histology. SLN metastases were detected in 9 out of 508 (1.8%) patients. In five patients only micrometastasis (

Original languageEnglish
Pages (from-to)520-522
Number of pages3
Issue number6
Publication statusPublished - Dec 2005


  • Breast
  • Carcinoma in situ
  • DCIS
  • Sentinel lymph node biopsy
  • Sentinel node mapping

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'Sentinel lymph node biopsy for localised ductal carcinoma in situ?'. Together they form a unique fingerprint.

Cite this